Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Current Assets for 4 consecutive years, with $137.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 33.15% to $137.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $137.7 million, a 33.15% decrease, with the full-year FY2024 number at $194.1 million, up 9.64% from a year prior.
  • Current Assets was $137.7 million for Q3 2025 at Century Therapeutics, down from $160.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $383.8 million in Q2 2022 to a low of $137.7 million in Q3 2025.
  • A 4-year average of $231.3 million and a median of $199.8 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: crashed 57.98% in 2023, then grew 26.16% in 2024.
  • Century Therapeutics' Current Assets stood at $319.7 million in 2022, then plummeted by 44.64% to $177.0 million in 2023, then increased by 9.64% to $194.1 million in 2024, then dropped by 29.03% to $137.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Current Assets are $137.7 million (Q3 2025), $160.2 million (Q2 2025), and $169.6 million (Q1 2025).